Page 163 - 2020_02-Haematologica-web

A CML Drosophila model for treatment screening
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin- 1-yl)-2-methylpyrimidin-4- ylamino)thia- zole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitu- mor activity in preclinical assays. J Med Chem. 2004;47(27):6658-6661.
23. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505.
24. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resis- tant ABL mutants. Cancer Res. 2006;66(11): 5790-5797.
25. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
26. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141.
27. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood. 2014;124(21):3135-3135.
28. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
29. Breccia M, Pregno P, Spallarossa P, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Ann Hematol. 2017;96(4):549-558.
30. Muller MC, Cervantes F, Hjorth-Hansen H, et al. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017;120:52-59.
31. Mahon F-X, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have main- tained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
32. Gonzalez C. Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics. Nat Rev Cancer. 2013;13(3):172.
33. Fogerty FJ, Juang JL, Petersen J, Clark MJ, Hoffmann FM, Mosher DF. Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis. Oncogene. 1999;18(1):219-232.
34. Bernardoni R, Giordani G, Signorino E, et al. A new BCR-ABL1 Drosophila model as a powerful tool to elucidate pathogenesis and progression of chronic myeloid leukemia. Haematologica. 2019;104(4):717-728.
35. Shirinian M, Kambris Z, Hamadeh L, et al. A Transgenic Drosophila melanogaster Model To Study Human T-Lymphotropic Virus
Oncoprotein Tax-1-Driven Transformation
In Vivo. J Virol. 2015;89(15):8092-8095.
36. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image
analysis. Nat Methods. 2012;9(7):671-675. 37. Freeman M. Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye. Cell.
1996;87(4):651-660.
38. Duffy JB. GAL4 system in Drosophila: a fly
geneticist's Swiss army knife. Genesis.
2002;34(1-2):1-15.
39. XinS,WengL,XuJ,DuW.TheroleofRBF
in developmentally regulated cell prolifera- tion in the eye disc and in Cyclin D/Cdk4 induced cellular growth. Development. 2002;129(6):1345-1356.
40. Cvetković VJ, Mitrović TL, Jovanović B, et al. Toxicity of dimethyl sulfoxide against Drosophila melanogaster. Biol Nyssana. 2015;6(2):91-95.
41. Singh J, Aaronson SA, Mlodzik M. Drosophila Abelson kinase mediates cell invasion and proliferation through two dis- tinct MAPK pathways. Oncogene. 2010;29 (28):4033-4045.
42. Xiong W, Rebay I. Abelson tyrosine kinase is required for Drosophila photoreceptor mor- phogenesis and retinal epithelial patterning. Dev Dyn. 2011;240(7):1745-1755.
43. Takahashi F, Endo S, Kojima T, Saigo K. Regulation of cell-cell contacts in developing Drosophila eyes by Dsrc41, a new, close rel- ative of vertebrate c-src. Genes Dev. 1996;10(13):1645-1656.
haematologica | 2020; 105(2)
397